Skip to content
AZAZAZ808080

Drawing based on the description in the official product monograph. No photo yet.

“80 mg tablets are beige, oval and biconvex tablets marked with "AZ" and "80" on one side and plain on the other side”

AZ 80 pill

Pill with imprint AZ 80 is brown, oval and has been identified as Osimertinib Mesylate 80 mg. It is used for lung cancer. It is supplied by Astrazeneca Canada Inc.

Sold in Canada

Osimertinib Mesylate 80 mg

Brand
Tagrisso
Imprint
AZ 80
Strength
80 mg
Used for
Lung cancer
Color
Brown
Shape
Oval
Form
Tablet
Manufacturer
Astrazeneca Canada Inc
Drug class
Cancer medicine (kinase inhibitor)
Sold in
Canada
DIN
02456222

Source: Health Canada's Drug Product Database and the official product monograph. Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Osimertinib pills and guides

What is Osimertinib used for?

Osimertinib is used for lung cancer.

Medicine type
Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label

Adjuvant Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)

TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Locally Advanced, Unresectable (Stage III) EGFR Mutation-Positive NSCLC

TAGRISSO is indicated for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

First-line Treatment of EGFR Mutation-Positive Metastatic NSCLC

TAGRISSO is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

First-line Treatment of EGFR Mutation-Positive Locally Advanced or Metastatic NSCLC

TAGRISSO in combination with pemetrexed and platinum-based chemotherapy is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Previously Treated EGFR T790M Mutation-Positive Metastatic NSCLC

TAGRISSO is indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

From the FDA-approved label on DailyMed (published Sep 25, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows AZ 80. The parts can be split between the two sides, so turn the pill over and check both.
  • It is brown, oval.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Sold in Canada as Tagrisso by Astrazeneca Canada Inc.

In Canada: prescription only.

Ingredients

Active: Osimertinib (Osimertinib Mesylate)

Other pills with imprint AZ 80

Same imprint, different listing. Check the color, size and maker against your pill.

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Osimertinib pills